CPS IC/BPS Amendment (2015)

Member only benefit! AUA Guidelines provide a comprehensive and rigorous summary of evidence relating to a variety of disease conditions, providing an indispensable resource for urologic education. The Clinical Problem Solving (CPS) Protocols guideline-based Case Scenarios were designed to help maximize the impact of the guidelines. The bladder disease complex includes a large group of patients with bladder and/or urethral and/or pelvic pain, lower urinary tract symptoms, and sterile urine cultures, many with specific identifiable causes. IC/BPS comprises a part of this complex. This guideline's purpose is to provide direction to clinicians and patients regarding how to: recognize interstitial cystitis (IC)/bladder pain syndrome (BPS); conduct a valid diagnostic process; and, approach treatment with the goals of maximizing symptom control and patient quality of life (QoL) while minimizing AEs and patient burden.

Target Audience

  • Urologists (Practicing; Recertification Candidates; International)
  • Residents

Learning Objectives

After completion of this activity, participants should be able to:

  1. Interpret and explain the appropriate diagnosis, prevention and treatment of the related guideline.
  2. Perform appropriate methods of evaluation and management according to the guideline.
  3. Analyze the risks and benefits for treatment according to the guideline.
  4. Integrate AUA guidelines into clinical practice.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
Course expires: 

Faculty Disclosures
Philip Hanno, MD: Astellas: Consultant or Advisor; Lilly: Consultant or Advisor; Afferent: Consultant or Advisor
Damara Kaplan, MD: Nothing to disclose            
Robert Moldwin, MD: Taris Biomedical: Consultant or Advisor, Scientific Study or Trial; Urigen Pharmaceuticals: Consultant or Advisor; Afferent Pharmaceuticals: Scientific Study or Trial
Thomas Rechtschaffen, MD: Astellas: Meeting Participant or Lecturer; Endo Pharmaceuticals: Meeting Participant or Lecturer
Planner Disclosures
Education Council        
Timothy Charles Brand, MD: Nothing to disclose   
Peter Robert Carroll, MD, MPH: NIH: Scientific Study or Trial; Department of Defense: Scientific Study or Trial; Myriad Genetics: Scientific Study or Trial; AUA Update: Leadership Position; Genomic Health: Scientific Study or Trial
Sam S. Chang, MD: Astellas: Consultant or Advisor; NIH: Scientific Study or Trial; Cold Genesys, Inc.: Scientific Study or Trial; GLG: Consultant or Advisor; Bayer: Consultant or Advisor
Pat Fox Fulgham, MD: Urology Clinics of North Texas: Investment Interest
Matthew Thomas Gettman, MD: Nothing to disclose
Inderbir Singh Gill, MD, MCh: Hansen Medical: Investment Interest; EDAP: Consultant or Advisor; Mimic: Consultant or Advisor
Christina Griffin (AUA Staff): Nothing to disclose
Misop Han, MD: Nothing to disclose
David Alan Hatch, MD: Pfizer: Scientific Study or Trial
Douglas A. Husmann, MD: Nothing to disclose 
Mark L. Jordan, MD, FACS: Nothing to disclose            
Louis Koncz, PA-C: American Medical Systems: Meeting Participant or Lecturer
Tracey Lynn Krupski, MD: Nothing to disclose
Cheryl Taylore Lee, MD: Endo Pharmaceuticals: Scientific Study or Trial
Yair Lotan, MD: Abbott: Scientific Study or Trial; Danone: Consultant or Advisor, Scientific Study or Trial; Cepheid: Scientific Study or Trial; Pacific Edge: Scientific Study or Trial; FKD: Scientific Study or Trial; MDxHealth: Consultant or Advisor; Biocancell: Scientific Study or Trial; Genomic Health: Scientific Study or Trial; GenomeDx Biosciences Inc.: Scientific Study or Trial; Photocure: Scientific Study or Trial
Jill A. Macoska, PhD: Nothing to disclose
Manoj Monga, MD: Fortec: Other; Endourology Society: Leadership Position; Practical Reviews in Urology: Health Publishing
Victor William Nitti, MD: Astellas: Health Publishing, Scientific Study or Trial; Allergan: Health Publishing, Scientific Study or Trial; Serenity Pharmaceuticals: Investment Interest
Gail S. Prins, PhD: Nothing to disclose
Lee Richstone, MD: Nothing to disclose
Karl-Dietrich Sievert, MD, PhD: AMS: Meeting Participant or Lecturer; Karl Storz: Meeting Participant or Lecturer; Medtronics: Meeting Participant or Lecturer, Scientific Study or Trial; Allergen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Neotract: Meeting Participant or Lecturer
Joseph A. Smith, Jr., MD: Nothing to disclose
Sean Patrick Stroup, MD: Intuitive Surgical: Meeting Participant or Lecturer; NeoTract: Meeting Participant or Lecturer
Chandru P. Sundaram, MD: Journal of Endourology and Videourology: Leadership Position; Sonacare, Inc.: Scientific Study or Trial; OnTarget Inc: Scientific Study or Trial; IAUA: Leadership Position
Edouard John Trabulsi, MD: Nothing to disclose 

Method of Participation

Learners will participate in this interactive online educational activity by completing a pre-test, reading the AUA Guideline, complete the slides and case studies, answering multiple choice questions, examining patient tools and resources and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete each activity: 2.0 hours

Release Date: July, 2015
Expiration Date: July, 2018

Accreditation Statement

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Non-physician Health Professionals

The AUA is not accredited to offer credit for non-physician health professionals. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence-Based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

Off-label or Unapproved Use of Drugs or Devices

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the product prescribing information for full disclosure of approved uses.

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty


The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

AUA Privacy and Confidentiality Policy


Contact Information

American Urological Association
Office of Education
1000 Corporate Blvd
Linthicum, MD 21090

Toll Free (U.S. only): 1-866-RING AUA (1-866-746-4282)
Phone: 410-689-3700
Fax: 410-689-3800

CME Information

For all inquiries regarding CME credit email: cme@AUAnet.org

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.